Physician profile
Michael V Boland
NPI 1023074143
$80,629.84
in general payments reported to CMS, 2019-2025
9 companies · $2,627 in 2025
The $2,627 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,417 · 2021: $12K · 2022: $46K · 2023: $4,791 · 2024: $13K · 2025: $2,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,950 · Travel and Lodging: $764 · Food and Beverage: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,157.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,950.00 |
| Travel and Lodging | $764.24 |
| Food and Beverage | $422.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare, INC. | $34,105.82 | 2021-2025 | |
| Carl Zeiss Meditec, INC. | $31,229.58 | 2019-2024 | Cirrus Hd-Oct, Forum, Forum Glaucoma Workplace |
| Abbvie INC. | $10,078.14 | 2022-2025 | |
| Janssen Research & Development, LLC | $4,225.00 | 2022 | |
| Allergan, INC. | $822.16 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $123.05 | 2024 | Forum Glaucoma Workplace |
| Alcon Vision LLC | $19.03 | 2025 | |
| Ivantis, INC | $14.84 | 2019 | |
| Lilly USA, LLC | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Boland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.